Press Release / Industry / Global Anxiety Disorders Treatment to Witness Sustainable Growth: In-depth Industry Analysis with Key Player’s Strategic Movement; Eli Lily & Company, AstraZeneca, Pfizer, and GlaxoSmithKline

Global Anxiety Disorders Treatment to Witness Sustainable Growth: In-depth Industry Analysis with Key Player’s Strategic Movement; Eli Lily & Company, AstraZeneca, Pfizer, and GlaxoSmithKline

The report analyzes the industry in terms of the drug category, therapy, and geography. This comprehensive study reveals the market estimate numbers for different market segments. Key industry dynamics, regulatory scenario, patent expiry of blockbuster drugs and strategic benchmarking and thorough competitive landscaping are discussed, spreading over 100 pages.

According to the World Health Organization (WHO), depression is the second-leading cause of disabilities, affecting more than 300 million populations across the globe. Thus, increasing prevalence of anxiety disorders such as depression has boosted the demand for effective treatment options, augmenting the market growth. Furthermore, raising awareness campaigns regarding anxiety disorders by the government or non-government bodies drive the industry growth. For instance, Anxiety and Depression Association of America (ADAA) started initiative named “BreaktheStigma”. This initiative is focused on raising awareness about anxiety and depression. Other factors such as new product developments and a growing number of companies investing in this market augment the growth significantly. However, patent expiry of major drugs has slow down the industry development since the last couple of years. For instance, Eli Lilly’s duloxetine delayed-release capsule (i.e. Cymbalta) for depression treatment has lost patent exclusivity in 2014. Owing to this, the revenue was declined significantly during the same period. In 2014, the company posted USD 1,614.7 million sales from Cymbalta, around 63% decrease compared to the previous year (USD 5,084.4 in 2014).

To request a free sample copy:
www.analystviewmarketinsights.com/request_sample/av125/

Key Takeaways
-Of the drug category, Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs) and Serotonin Reuptake Inhibitors (SSRIs) achieved the highest revenue share. In 2017, these segments recorded more than 60% revenue share collectively. The boost in demand for anxiety therapeutics coupled with the rising in a number of companies investing to develop new anxiety drugs drives the market revenue.
-The study further includes a detailed analysis of top-selling anxiety therapeutics such as Abilify, Cymbalta, Lyrica, Vyvanse among others.
-On contrary, anxiety therapies are growing with the highest CAGR of 3.7% owing to high efficiency in treating anxiety-related disorders and rising demand in developed regions such as North America and Europe
-Of the different therapies, Transcranial Magnetic Stimulator and Fischer Wallace Stimulator are the largest revenue-generating segment, recorded over USD 1,500 million revenue collectively throughout the study period.
-In terms of indications, Major Depressive Disorder (MDD), and Obsessive-Compulsive Disorder (OCD) amounted to the largest revenue generating segment. MDD indicative anxiety problem is one of the highest affected condition among the young population.
-The industry is fragmented in nature. Companies such as Eli Lily and Company, Pfizer, Inc., AstraZeneca plc, H. Lundbeck and GlaxoSmithKline plc are leading players in this industry, accounted for more than 60% share of the global market revenue.
-Strategic initiatives to expand their presence in developing regions coupled with a huge investment in research activities to develop effective therapeutics or therapies helped these players to sustain in this market.
-For instance, in September 2016, Pfizer, Inc. introduced “Moodivator” app to help encourage, motivate and support people with depression. This app includes simple features such as goal setting and mood tracking that leverage the best principle in managing depression

Browse full report with in-depth TOC on “Anxiety Disorders Treatment Market, By Drug Category (SSRIs, TCAs, SNRIs, MAOIs, Anticonvulsants, and Others), By Therapy (TMS, ECT, CBT, and FWS), and Geography (NA, EU, APAC, and RoW) – Analysis, Share, Trends, Size, & Forecast From 2014 – 2025” at

www.analystviewmarketinsights.com/report-highlight-anxiety-disorders-treatment-market-125/

The scope of the Report:
-The market, by Drug Category: Selective Serotonin Reuptake Inhibitors (SSRIs), Tricyclic Antidepressants (TCAs), Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs), Monoamine oxidase inhibitors (MAOIs) and Anticonvulsants
-The market, by Therapy: Transcranial Magnetic Stimulator, Electroconvulsive Therapy (ECT), Cognitive Behaviour Therapy (CBT) and Fischer Wallace Stimulator
-The market, by Region: North America, Europe, Asia Pacific, Latin America, Middle East and Africa and Rest of the World; Market, by Country: U.S., Canada, Germany, France, India, and China;

Key players profiled in this report with special attention on competitive landscape includes, (can be further customized to include an additional 10 profiles of companies):
-Eli Lily & Company
-Bristol-Myers Squibb Company
-AstraZeneca plc
-Johnson & Johnson
-GlaxoSmithKline
-Pfizer, Inc.

Key benefits of the report:
-The report presents a macro and micro-level outlook regarding the industry. Thus, it becomes easy for our clients to perceive the business landscape and take a glimpse of their own standing in it.
-A thorough analysis of relevant statistical data to estimate the market paradigms
-Exceptional understanding of the region and country-specific markets. The report will answer some of the toughest questions regarding the market shares, sizes, forecasts segmentations, and growth specific to the countries.
-Well-designed strategic framework analyzes the market movements including regional expansion, mergers & acquisitions, and new product developments